Systemic treatments are also driven by the breast cancer subtype, typically broken down by expression of human epidermal growth factor receptor 2 (HER2) and hormone receptors, consisting of estrogen receptors (ER) and progesterone receptors (PR). Here, ERBB2 is linked to breast cancer.